A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine

ConclusionsThis study therefore proved that human cancer cell-derived RPS3, a novel TLR4 ligand, has great potential as an adjuvant in tumor-specific antigen DC-based vaccines.

http://link.springer.com/10.1186/s40425-019-0539-7

Source: Journal for Immunotherapy of Cancer - February 28, 2019 Category: Cancer & Oncology Source Type: research